4//SEC Filing
Auspex Pharmaceuticals, Inc. 4
Accession 0001209191-15-039556
CIK 0001454189operating
Filed
May 5, 8:00 PM ET
Accepted
May 6, 6:18 PM ET
Size
10.1 KB
Accession
0001209191-15-039556
Insider Transaction Report
Form 4
PROEHL GERALD T
Director
Transactions
- Disposition from Tender
Common Stock
2015-05-05−1,466→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2015-05-05−13,333→ 0 totalExercise: $6.57Exp: 2024-01-09→ Common Stock (13,333 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2015-05-05−6,667→ 0 totalExercise: $18.13Exp: 2024-05-05→ Common Stock (6,667 underlying)
Footnotes (2)
- [F1]Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated March 29, 2015, among the Issuer, Teva Pharmaceuticals Industries Ltd. ("Parent"), and Aurum Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub") in exchange for a cash consideration of $101.00 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation (the "Merger").
- [F2]This option, which is fully vested, was cancelled in the Merger in exchange for a cash payment equal to $101.00 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the stock option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Documents
Issuer
Auspex Pharmaceuticals, Inc.
CIK 0001454189
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001454189
Filing Metadata
- Form type
- 4
- Filed
- May 5, 8:00 PM ET
- Accepted
- May 6, 6:18 PM ET
- Size
- 10.1 KB